Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A of the Securities Exchange Act of 1934, indicates that the materials are intended to provide further information to shareholders in connection with the company's upcoming decisions. The filing confirms that no additional filing fee is required for these materials. The proxy statement and additional materials are a standard part of the shareholder voting process, allowing Bristol-Myers Squibb's shareholders to be fully informed before casting their votes on corporate matters.

Bristol-Myers Squibb, a leading pharmaceutical company, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A of the Securities Exchange Act of 1934, indicates that the materials are intended to provide further information to shareholders in connection with the company's upcoming decisions. The filing confirms that no additional filing fee is required for these materials. The proxy statement and additional materials are a standard part of the shareholder voting process, allowing Bristol-Myers Squibb's shareholders to be fully informed before casting their votes on corporate matters.